SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla's earnings release is driving significant speculation, with community members debating whether the results will justify the stock's valuation amid broader concerns about the EV sector. Discussions range from potential impacts of Elon Musk's compensation package to the influence of AI and robotaxi advancements on the company's future. Traders are strategizing around potential volatility, anticipating a substantial price swing post-earnings.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending amid news of a potential acquisition in Australia and positive commentary surrounding a recent CEO interview. The community is closely watching for updates on the deal, speculating about its impact on the company's market position and potential government involvement. Discussions also highlight UAMY's role in critical minerals and rare earth elements, especially with increasing geopolitical focus on supply chains.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels is trending as the community discusses significant call option sweeps and potential government contracts related to rare earth processing, particularly with the "Donald Project". Bullish sentiment is fueled by the company's existing capabilities and capacity in the uranium and rare earth elements sector, contrasting with competitors, with some anticipating a potential valuation catch-up to other players in the sector. The stock's resilience amidst a broader market downturn is also driving interest.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending due to a recent breakthrough in quantum computing with HSBC, demonstrating improved bond trading predictions, which has sparked excitement about the company's leadership in the sector. The community is discussing IBM's growing AI and quantum capabilities and the potential impact on its stock value. Broader market context includes IBM's strategic shift towards AI and cloud computing.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending amidst anticipation for upcoming earnings, with the community eager for updates on partnerships and production milestones. Discussions revolve around the potential impact of earnings on the stock's price, as well as speculation regarding a possible partnership with Panasonic and the unveiling of a second OEM. Despite some concerns about market conditions and short selling, many investors express long-term confidence in the company's technology and future prospects in the battery sector.

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded in 1989 and is headquartered in Los Angeles, CA.

Armata Pharmaceuticals Inc

Armata Pharmaceuticals is trending due to positive Phase 2a diSArm study results, highlighting the efficacy of their phage therapy for S. aureus bacteremia, with community members discussing potential for advancement to Phase 3. Bullish investors are optimistic about the news, while bears debate the likelihood of a pump and dump and potential future offerings. The company's innovative approach to combating antibiotic-resistant infections is drawing attention in the biotech sector.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics ($ARCT) is trending due to recent interim data from its inhaled mRNA therapy for cystic fibrosis, which showed mixed results, triggering a sharp sell-off and subsequent bounce. The community is discussing whether the overreaction presents a buying opportunity, focusing on positive aspects of the data such as mucus reduction, and potential catalysts like CSL royalties and lawsuit updates. Broader discussions involve the company's pipeline, potential buyout scenarios, and the overall sentiment in the biotech sector.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is trending amid discussions about its AI advancements, particularly the Willow chip and Gemini AI, with some analysts raising price targets. Community members are also closely watching the competitive landscape, including OpenAI's activities, and assessing the potential impact on Google's market share. Several messages reference a DoorDash partnership with Waymo for autonomous delivery.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

Lam Research is trending amid discussions about earnings, with some celebrating a significant beat while others express concerns about tariffs and broader market conditions. The community is focused on whether the stock's upward momentum can be sustained. Bullish sentiment seems to be building around the company's potential in AI and memory markets.

Beasley Broadcast Group, Inc. is multi-platform media company, which engages in the operation of radio stations in the United States. The firm offers marketing solutions across event platforms. It operates through the following business segments: Audio, Digital, and Other. The company was founded by George G. Beasley in 1961 and is headquartered in Naples, FL.

Beasley Broadcast Group Inc - Ordinary Shares - Class A

Beasley Broadcast Group is trending as traders discuss its low float and potential for a significant upward move, with some comparing it to previous runners. Community members are closely watching volume and key breakout levels, anticipating a possible surge. Chatter also mentions the company's fundamentals, including cash position and revenue, alongside discussions of debt and potential financial strategies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Retail chatter around Avalo rose ahead of an Oppenheimer conference call set to discuss its lead hidradenitis suppurativa drug, AVTX-009, now in a mid-stage trial with topline results expected in 2026.</li><li>Analysts at H.C. Wainwright, Oppenheimer, TD Cowen, and Cantor Fitzgerald maintain bullish views on Avalo, with price targets ranging from $25 to $35 and expectations that AVTX-009 could outperform AbbVie’s rival therapy.</li><li>On Stocktwits, sentiment turned ‘extremely bullish’ as message activity surged; users highlighted fresh opportunities and long-term upside.</li></ul>Shares of Avalo Therapeutics gained 0.4% in premarket trading on Wednesday amid upbeat investor sentiment ahead of an Oppenheimer analyst call focused on its lead drug candidate, AVTX-009, for hidradenitis suppurativa.&nbsp;The stock is currently trading at a nearly 18-month high.&nbsp;<h2 class="st-heading-2">Pipeline And Trial Progress</h2>Earlier this month, Avalo said it had dosed the first patient in the LOTUS study. The randomized, double-blind, placebo-controlled trial is testing two dosing regimens of AVTX-009, with top-line results expected in 2026.The study’s primary endpoint is the proportion of patients achieving HiSCR75, a 75% reduction in abscess and nodule count at week 16, while secondary measures include HiSCR50 and HiSCR90 response rates, improvements in skin pain and lesion severity, and safety outcomes.AVTX-009 targets interleukin-1β, a cytokine involved in the inflammatory cascade driving HS and several other autoimmune diseases. The drug’s mechanism builds on clinical validation seen with other IL-1 inhibitors and aims to deliver higher potency and longer durability.<h2 class="st-heading-2">Analyst Views&nbsp;</h2>Avalo has drawn attention from multiple brokerages since restarting its HS program this year.In September, H.C. Wainwright raised its price target on Avalo Therapeutics to $25 from $15 and reiterated a ‘Buy’ rating, saying AbbVie’s latest hidradenitis suppurativa data validated the IL-1 pathway but capped efficacy at 45%–50% HiSCR75.Earlier that month, Oppenheimer recommended investors be buyers of Avalo shares ahead of lutikizumab’s open-label Phase 2 data, forecasting “strong results” and expecting AVTX-009, with multiple advantages over lutikizumab, to deliver “at least as good as, and potentially better, efficacy” when LOTUS trial results&nbsp;are read out in mid-2026. The firm maintained an ‘Outperform’ rating and a $35 price target.Separately, TD Cowen initiated coverage with a ‘Buy’ rating, citing AVTX-009’s Phase 2 study in hidradenitis suppurativa and highlighting the high unmet need in a heterogeneous patient population, estimating over $1 billion sales potential.&nbsp;Cantor Fitzgerald also began coverage with an ‘Overweight’ rating, describing Avalo as a clinical-stage biotech focused on autoimmune diseases and noting that AVTX-009, an IL-1N2 antibody, is expected to have a mid-2026 readout.<h2 class="st-heading-2">Stocktwits Traders See Long-Term Upside</h2>On Stocktwits, retail sentiment for Avalo was ‘extremely bullish’ amid a 20% surge in 24-hour message volume.One user noted that the setup still offered opportunities and encouraged others to stay tuned.<stembedurl>https://stocktwits.com/topstockalerts/message/632967338</stembedurl>Another user suggested that Avalo looked like a strong buy and could deliver twentyfold returns for investors willing to hold long term.<stembedurl>https://stocktwits.com/WallGoodman/message/632883343</stembedurl><a href="https://stocktwits.com/symbol/AVTX">Avalo’s stock</a> has more than doubled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Avalo’s stock has more than doubled so far in 2025. (Photo credit: Getty Images)

Avalo Therapeutics Stock Rises Premarket Ahead Of Oppenheimer Call On Lead Hidradenitis Drug

Retail chatter around Avalo rose ahead of an Oppenheimer conference call set to discuss its lead hidradenitis suppurativa drug, AVTX-009, now in a mid-stage trial with topline results expected in 2026.

Equity

Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry...

The Lustgarten Foundation Appoints Two New Board Members

The Lustgarten Foundation Appoints Two New Board Members The Lustgarten Foundation Appoints Two New Board Members PR Newswire WOODBURY, N.Y., June 13, 2024 Richard Barakat, MD, and Aaron Kantoff join...

Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades

Unlock the potential of Avalo Therapeutics with AVTX-009, a promising drug for hidradenitis suppurativa. Oppenheimer upgrades to Outperform, foreseeing Phase 2 progress and market distinction...

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent DirectorsBoard of Director appointments in conjunction with Avalo's recent acquisition of...

Avalo Therapeutics (AVTX) stock slips after earnings: buy the dip?

Avalo Therapeutics (AVTX) stock price nosedived on Monday after the company published relatively weak financial results. It tumbled by over 23.5% in the pre-market session and reached a low of...

Avalo Therapeutics EPS of -$114.00, revenue of $1.92M beats by $0.72M

Avalo Therapeutics EPS of -$114.00, revenue of $1.92M beats by $0.72M...

Avalo Reports 2023 Financial Results and Provides Business Updates

Acquired AVTX-009, Phase-2 ready anti-IL-1 mAb, in March 2024Increased cash position with private placement financing in March 2024 providing up to $185 million, including initial upfront investment...

12 titres de soins de sant  en mouvement lors de la pr -ouverture le 29/03/2024

Gagnants
Le titre Avalo Therapeutics (NASDAQ:AVTX) a mont vendredi de 289,05% 18,48 dollars lors de la session pre-market.
Le titre Xilio Therapeutics (NASDAQ:XLO) a grimp de 205,16% 1,95...

12 titoli sanitari in movimento, pre-market del 29/03/2024

Titoli in rialzo
Le azioni di Avalo Therapeutics (NASDAQ:AVTX) sono cresciute del 289,05% a 18,48 dollari durante la sessione pre-market di venerd .
Il titolo Xilio Therapeutics (NASDAQ:XLO) salito...

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Current Price	$15.78
Prev Close	$17.43
Open	$17.06
Dividend Yield	0.00%
50-Day Moving Average	$11.60
Beta	1.39
Avg. Volume	427,912.29
PE Ratio	-1.86

52-Week High	$19.41
52-Week Low	$3.39
Market Capitalization	$229.25M
EPS (Annual)	-$20.91
Price to Book	1.81
Revenue Per Employee	$19,173.91
Enterprise Value/EBITDA	N/A

AVTX
Avalo Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AVTX News

AVTXAvalo Therapeutics Inc